Table 1.
Baseline demographics.
| Characteristic, n (%) | Therapeutic upon admission |
Newly initiated |
||||||
|---|---|---|---|---|---|---|---|---|
| Underweight (n = 26) |
Normal/overweight (n = 200) |
Obese (n = 200) |
Morbidly obese (n = 159) |
Underweight (n = 9) |
Normal/overweight (n = 166) |
Obese (n = 152) |
Morbidly obese (n = 52) |
|
| Age, mean* | 76.7 | 77.8 | 71.4 | 65.6 | 75.5 | 70.3 | 66.6 | 56.3 |
| Sex, male$ | 4 (15.4) | 98 (49) | 98 (49) | 76 (47.8) | 2 (22.2) | 87 (52.4) | 73 (48) | 24 (46.2) |
| Weight, mean (kg)* | 44.9 | 73.4 | 98.7 | 137 | 63.1 | 108 | 136.5 | 184.5 |
| BMI, mean (kg/m2)* | 16.3 | 25.3 | 34.1 | 48.2 | 16.5 | 25.1 | 33.5 | 46.7 |
| Race | ||||||||
| Caucasian | 24 (92.3) | 152 (76) | 129 (64.5) | 111 (69.8) | 7 (77.8) | 117 (70.5) | 110 (72.4) | 35 (67.3) |
| Black | 2 (7.7) | 44 (22) | 64 (32) | 47 (29.6) | 2 (22.2) | 45 (27.1) | 39 (25.7) | 15 (28.8) |
| Other | 0 | 4 (2) | 7 (3.5) | 1 (0.6) | 0 | 4 (2.4) | 3 (2.7) | 2 (3.8) |
| Current smoker | 0 | 21 (10.5) | 17 (8.5) | 17 (10.7) | 3 (33.3) | 19 (11.4) | 18 (11.8) | 8 (15.4) |
| Interacting medication | 5 (19.2) | 33 (16.5) | 38 (19) | 17 (10.7) | 3 (33.3) | 69 (41.6) | 79 (52) | 28 (53.8) |
| Amiodarone | 4 (15.4) | 25 (12.5) | 33 (16.5) | 12 (7.5) | 2 (22.2) | 59 (35.5) | 72 (47.4) | 22 (42.3) |
| Carbamazepine | 0 | 1 (0.5) | 1 (0.5) | 0 | 0 | 0 | 0 | 2 (3.8) |
| Fluconazole‡ | 0 | 3 (1.5) | 0 | 2 (1.3) | 1 (11.1) | 6 (3.6) | 2 (1.3) | 6 (11.5) |
| Metronidazole | 1 (3.8) | 7 (3.5) | 4 (2) | 2 (1.3) | 0 | 12 (7.2) | 9 (5.9) | 5 (9.6) |
| Phenobarbital | 0 | 1 (0.5) | 1 (0.5) | 0 | 0 | 1 (0.6) | 0 | 0 |
| Sulfamethoxazole/trimethoprim | 0 | 2 (1) | 2 (1) | 2 (1.3) | 0 | 4 (2.4) | 2 (1.3) | 1 (1.9) |
| Indication | ||||||||
| Atrial fibrillation | 15 (57.7) | 138 (69) | 144 (72) | 96 (60.4) | 3 (33.3) | 25 (15.1) | 26 (17.1) | 16 (30.8) |
| VTE treatment | 9 (34.6) | 42 (21) | 53 (26.5) | 55 (34.6) | 4 (44.4) | 78 (47) | 56 (36.8) | 19 (36.5) |
| Valve repair or replacement | 1 (3.8) | 30 (15) | 23 (11.5) | 10 (6.3) | 1 (11.1) | 42 (25.3) | 61 (40.1) | 15 (28.8) |
| Other | 1 (3.8) | 4 (2) | 6 (3) | 4 (2.5) | 0 | 1 (.6) | 4 (2.6) | 3 (5.8) |
*
p Value < 0.05 in both cohorts.
$
p Value < 0.05 in cohort A.
‡
p Value < 0.05 in cohort B.
VTE, venous thromboembolism.